Research
Hormonal
The management of type 2 diabetes (T2D) has evolved significantly with the emergence of diverse medication classes.
Healthcare professionals should be aware of the evolving medication landscape for T2D.
StrongSupportsmedium confidence
The management of type 2 diabetes (T2D) has evolved significantly with the emergence of diverse medication classes.
Why this rating
The abstract discusses a comprehensive overview of medication classes.
Source
Commercially Available Injectables in Diabetes – Insulin, Incretins, and More
Jothydev Kesavadev et al. · International Journal of Diabetes and Technology · 2023
DOI 10.4103/ijdt.ijdt_29_23
reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →